In short
Elotuzumab is an innovative drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. These trials aim to evaluate the safety and effectiveness of elotuzumab alone or in combination with other drugs in patients with relapsed or refractory multiple myeloma. The research explores various dosing regimens and combination therapies to improve outcomes for patients who have limited treatment options.
At a glance
- Drug Name
- Elotuzumab (also known as HuLuc63, Empliciti)
- Type of Drug
- Humanized monoclonal antibody targeting SLAMF7
- Target Disease
- Multiple Myeloma (relapsed/refractory)
- Common Combinations
- Lenalidomide, Pomalidomide, Bortezomib, Dexamethasone
- Administration
- Intravenous infusion
- Dosing Schedules
- Varies by trial; often weekly in initial cycles, then less frequent
- Key Outcomes Measured
- Progression-free survival, Overall response rate, Overall survival
- Special Populations
- Elderly patients, Post-transplant patients
- Novel Approaches
- Combination with other antibodies, Use in maintenance therapy
What is Elotuzumab?
Elotuzumab is a medication used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is known by several names, including Empliciti™, BMS-901608, and HuLuc63. Elotuzumab is a type of drug called a monoclonal antibody, which means it's a laboratory-made protein that mimics the immune system's ability to fight harmful cells.
How Elotuzumab Works
Elotuzumab works by targeting a specific protein called SLAMF7, which is found on the surface of myeloma cells and natural killer (NK) cells. By binding to this protein, elotuzumab helps to enhance the ability of NK cells to recognize and kill myeloma cells. This process is known as antibody-dependent cell-mediated cytotoxicity (ADCC). In simpler terms, elotuzumab helps your immune system to better identify and destroy cancer cells.
Conditions Treated
Elotuzumab is primarily used to treat multiple myeloma, particularly in cases where the disease has returned or has not responded to previous treatments. This is known as relapsed or refractory multiple myeloma. It's often used in patients who have already tried other treatments, including those who have received prior anti-CD38 antibody therapy.
How Elotuzumab is Administered
Elotuzumab is typically given as an intravenous (IV) infusion, which means it's administered directly into your bloodstream through a vein. The dosage and frequency can vary depending on the specific treatment plan, but a common schedule is:
- 10 mg/kg weekly (on days 1, 8, 15, and 22) for the first two 28-day cycles
- 20 mg/kg every 4 weeks (on day 1) for subsequent cycles
Before receiving elotuzumab, you'll usually be given pre-medications to help prevent potential infusion reactions. These may include:
- An antihistamine (like diphenhydramine)
- A histamine-2 blocker (like ranitidine)
- Acetaminophen (Tylenol)
Combination Therapies
Elotuzumab is often used in combination with other drugs to enhance its effectiveness. Some common combinations include:
- Elotuzumab with lenalidomide and dexamethasone
- Elotuzumab with pomalidomide and dexamethasone
- Elotuzumab with carfilzomib, lenalidomide, and dexamethasone
- Elotuzumab with bortezomib
These combinations are designed to attack multiple myeloma cells in different ways, potentially improving the overall effectiveness of the treatment.
Current Clinical Trials
Several clinical trials are currently underway to further investigate the effectiveness of elotuzumab in various treatment scenarios. Some notable trials include:
- A study comparing elotuzumab monotherapy to other combination therapies in relapsed/refractory multiple myeloma
- A trial examining elotuzumab in combination with pomalidomide as maintenance therapy after a second autologous stem cell transplant
- A study investigating the combination of elotuzumab with belantamab mafodotin, another targeted therapy for multiple myeloma
Potential Side Effects
Like all medications, elotuzumab can cause side effects. Common side effects may include:
- Fatigue
- Diarrhea
- Fever
- Constipation
- Cough
- Muscle spasms
More serious side effects, although less common, can include infusion reactions and an increased risk of infections. It's important to discuss potential side effects with your healthcare provider.